SCHEMBL25840815

SCHEMBL25840815

COc1cc(-c2ncco2)c(-c2ccc3c(N)cnnc3c2)cc1B(O)O

nearest known ligand 0.41

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 18/20 0.41
IMPDH2 P12268 1/20 0.33
DHFR P00374 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25299099 0.96 PDE10A (0.38) PDE10AIMPDH2DHFR
SCHEMBL26067392 0.94 PDE10A (0.39) PDE10AIMPDH2DHFR
SCHEMBL25260407 0.90 PDE10A (0.36) PDE10A
SCHEMBL25840834 0.87 LCK (0.33) PDE10A
SCHEMBL25841364 0.85 PDE10A (0.41) PDE10ADHFR
SCHEMBL26067402 0.84 LCK (0.32) PDE10A
Formic Acid SCHEMBL25296753 0.83 LCK (0.32)
SCHEMBL25841369 0.83 PDE10A (0.39) PDE10ADHFR
SCHEMBL25261024 0.82 CDK4 (0.41) PDE10ADHFR
SCHEMBL25840710 0.81 PLG (0.34) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PDE10A 1950/4885IMPDH2 1838/4885DHFR 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.